Last reviewed · How we verify

NCT06766474

The Rule of Bupivacaine Hydrochloride in Skin Graft Donor Site

Completed Phase 2 Last updated 13 January 2025
What this trial tests

Phase 2 trial testing Bupivacain in Skin Graft Complications in 90 participants. Completed in 30 October 2024.

Timeline
1 March 2023
Primary endpoint
15 October 2024
30 October 2024

Quick facts

Lead sponsorMinia University
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment90
Start date1 March 2023
Primary completion15 October 2024
Estimated completion30 October 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Minia University

Who can join

Adults 18 to 60, any sex, with Skin Graft Complications or Pain Management. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Split Thickness Skin Graft is frequently utilized for reconstructing skin loss of various causes. Unfortunately, the donor site of the STSG has an unavoidable, annoying post-operative pain

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Bupivacain

Trials testing the same drug.

Other Minia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06766474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing